CIPLA Share Price Performance
₹0
-1490.90 (-100.00%)
Price ₹0
Fair Value₹1,456.73
Share Pricen/a
Narrative Update • Jun 22
Cipla Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 46 Fair Values set on narratives written by author
CIPLA Community Narratives
AN
Fair Value
·Fair Value ₹1.46k 1.3% undervalued intrinsic discount
Emerging Markets And Chronic Therapies Will Open New Horizons
0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
Emerging Markets And Chronic Therapies Will Open New Horizons
Cipla looks set to benefit as more people in India, Africa, and other fast-growing regions need long-term medicines, while new specialty-style copycat drugs and online pharmacy efforts could lift growth over time. The catch is that tough pricing in the U.S. and strict regulators could squeeze profits if key product launches or factory approvals don’t go smoothly.Read more
AN
₹1.46k
1.3% undervalued intrinsic discount
Fair Value
Revenue
10.84% p.a.
Profit Margin
15.24%
Future PE
28.99x
Price in 2029
₹2.07k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
CIPLA: Fair Outlook As Respiratory Diagnostics And US Generics Pipeline Evolve
Fair Value: ₹1.46k 1.3% undervalued intrinsic discount
26 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cipla Limited Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 23, 2026
- 48.02
- 64.75%
- 13.94%
- 0.7%
About CIPLA
- Founded
- 1935
- Employees
- 31369
- CEO
- WebsiteView website
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
